Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906230 | 0.84 | PDE3A (0.49) | PDE10APDE3APDGFRBPDGFRAACHE | |
| SCHEMBL29055042 | 0.81 | PDE3A (0.57) | PDE10APDE3APDGFRBPDGFRAACHE | |
| SCHEMBL6700740 | 0.79 | KDM1A (0.48) | PDE3APDGFRBPDGFRA | |
| SCHEMBL1132415 | 0.78 | PDGFRB (0.51) | PDE3APDGFRBPDGFRAACHEBACE1 | |
| SCHEMBL906243 | 0.78 | KIT (0.59) | PDE3APDGFRBPDGFRAACHEBACE1 | |
| SCHEMBL906228 | 0.77 | PDGFRB (0.56) | PDGFRBAURKA | |
| SCHEMBL29055060 | 0.76 | PDE3A (0.50) | PDE10APDE3APDGFRBPDGFRAACHE | |
| SCHEMBL29055020 | 0.75 | ENPP1 (0.62) | PDE10APDE3APDGFRBPDGFRAACHE | |
| SCHEMBL29055063 | 0.75 | KIT (0.55) | PDE10APDE3APDGFRBPDGFRAACHE | |
| SCHEMBL2390546 | 0.71 | PDGFRB (0.73) | PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8022071-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-1309568-B1 | [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor | MILLENNIUM PHARM INC (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2277877-A1 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7560461-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1964839-A2 | Quinazoline derivatives as kinase inhibitors | Millennium Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1315715-B1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7329655-B2 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-6982266-B2 | N-(4-indol-5-yloxyphenyl){4-[6-methoxy-7-(2-methoxyethoxy)quinazolin-4-yl]piperazinyl}carboxamide for example; antiproliferative agents which inhibit phosphorylation of kinases such as tyrosine kinase; cancer, arteriosclerosis | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050288297-A1 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050101609-A1 | Quinazoline derivatives as kinase inhibitors | KYOWA HAKKO KOGYO CO, LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-09 | — | — | US | disclosed |
| EP-1315715-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309568-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016361-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016351-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDE10A 983/4885PDE3A 683/4885PDGFRB 10/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDE10A 983/4885PDE3A 683/4885PDGFRB 10/4885 |
| US-20040176594-A1 | Nitrogenous heterocyclic compounds | WNK2, NPR1, NPR3 | PDE10A 696/4885PDE3A 594/4885PDGFRB 9/4885 |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDE10A 983/4885PDE3A 683/4885PDGFRB 10/4885 |
| US-20050101609-A1 | Quinazoline derivatives as kinase inhibitors | TNNI3K, PDGFRA, TEK | PDE10A 1327/4885PDE3A 895/4885PDGFRB 4/4885 |
| US-20090176780-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | WNK2, CDK5, WNK1 | PDE10A 765/4885PDE3A 690/4885PDGFRB 6/4885 |
| US-20050288297-A1 | Quinazoline derivatives as kinase inhibitors | WNK2, WNK1, WNK3 | PDE10A 983/4885PDE3A 683/4885PDGFRB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.